Publications by authors named "Nicholas M Ruel"
Article Synopsis
- - 6-Mercaptopurine (6-MP) is commonly used for leukemia and inflammatory bowel disease, but it has serious side effects like gastrointestinal issues and liver toxicity, which can cause patients to stop treatment and increase relapse risk.
- - Research has identified the SLC43A3 gene, which encodes the ENBT1 transporter responsible for moving 6-MP into human cells, particularly in the gastrointestinal tract, bone marrow, and liver, though its connection to 6-MP side effects is still unclear.
- - By studying both human and mouse models, findings indicate that the ENBT1 transporter functions similarly in both species, suggesting that mouse models could be useful for understanding how changes in ENBT1 impact
6-Mercaptopurine (6-MP) is used extensively in the treatment of acute lymphoblastic leukemia (ALL) and inflammatory bowel diseases. Our laboratory determined previously, using a recombinant HEK293 cell model, that the -encoded equilibrative nucleobase transporter 1 (ENBT1) transports 6-MP into cells and significantly impacts the cytotoxicity of 6-MP in that model. To further investigate the clinical relevance of this finding, we now extend this work to an analysis of the impact of /ENBT1 expression and function on 6-MP uptake and cytotoxicity in leukemic lymphoblasts, the therapeutic target of 6-MP in ALL.
View Article and Find Full Text PDF6-Mercaptopurine (6-MP) is a nucleobase analog used in the treatment of acute lymphoblastic leukemia and inflammatory bowel disorders. However, the mechanisms underlying its transport into target cells have remained elusive. The protein encoded by SLC43A3_1 [equilibrative nucleobase transporter 1 (ENBT1)] has recently been shown to transport endogenous nucleobases.
View Article and Find Full Text PDF